We are the Pannexin company
Developing life transforming therapies
based on blocking Pannexin 1 channels
Targeting chronic pain,
and other severe diseases
Our focus is to develop life- transforming therapies, based on blocking Pannexin1 channels.
We are the first in transforming this new pharmacological target into a new therapeutic approach for many severe diseases with high unmet medical need.
Discover our science
Panx1 is a new, exciting and validated pharmacological target with applications in many therapeutic areas and diseases like pain, cancer, autism, epilepsy, migraine, inflammation.See our science
David Bravo PhD
Chief Executive Officer
Neuroscientist with 10 years of experience in drug discovery and innovation.
Thomas Gerlach PhD
Chief Strategic Officer
Biochemist with over 30 years of experience in global pharma development, sales and venture capital.
Gerhard Gross PhD
Chief Scientific Officer
Chemist with 35 years of experience in drug discovery and development - 14 FDA approved drugs